GT Urological, LLC - "Research & Development"

GT Urological Research & Development Efforts

Stress Urinary Incontinence (SUI) is a frequently debilitating disease which can severely curtail the activities of those who suffer from it. SUI often occurs in males following prostate cancer surgery and in females; SUI may be the result of damage incurred during child birth or as a result of the aging process. It is estimated that over 13 million Americans spend more than $2 billion a year on products to manage urinary incontinence. The current market of over $2 billion is expected to grow as life expectancy increases and the overall population increases.

At GT Urological, LLC, we are actively involved in the development of novel implantable devices for the treatment of stress or mixed urinary incontinence in men and women. These efforts have been financed, in part, through Small Business Innovation Research (SBIR) grants funded by the National Institutes of Health - National Institute of Diabetes, Digestive and Kidney Diseases (NIH-NIDDK). Our efforts are further aided by company president Gerald Timm's staff appointments in the Departments of Urological Surgery and Biomedical Engineering at the University of Minnesota.

The company's core technology employs mechanisms which allow the user to occlude (prevent urinary leakage) or remove the occlusion to allow unobstructed urinary voiding at will. This concept borrows from our previous NIH sponsored research and includes mechanical, electro-mechanical, magnetic and drug elution technologies. GT Urological's goal is to improve on existing implantable technologies for urinary incontinence by developing a device which:

Provides the user "on demand" control of urinary voiding functions
Improves mechanical reliability
Decreases the incidence of urethral injury and infection
Reduces surgical costs by greatly simplifying pre-operative and operative procedures

The company is currently following a path which would allow commercial introduction of the device for use in males in 2011 and in females in 2013.

GT Urological has several issued patents and several patents pending on a variety of technical platforms. While our technology is currently being developed for use in the field of urinary incontinence, it also has applicability in the areas of gastro-esophageal reflux disease (GERD) and fecal incontinence. Development in these fields may be accomplished by licensing of these technologies.

E-mail: info@gturo.com